Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Hodgkin Lymphoma

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Circulating Tumor DNA in Colorectal Cancer: Insights From the SWOG 80702 and BESPOKE Studies

Video Series

BESPOKE: ctDNA Clearance During and After ACT

Videos

John Marshall, MD​, and Mark Lewis, MD​, discuss how circulating tumor DNA (ctDNA) testing in colorectal cancer offers promising clinical utility across the care continuum, from early detection to treatment monitoring, with trials like BESPOKE and SWOG 80702 demonstrating its potential to guide personalized therapy decisions, predict outcomes based on minimal residual disease status, complement traditional imaging in challenging cases, and transform patient care through a patient-centric approach that requires ongoing research to establish standardized protocols.

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for early detection, treatment monitoring, and recurrence surveillance in patients with colorectal cancer (CRC).

The Role of ctDNA in CRC

Panelists discuss how the BESPOKE study’s innovative design, carefully selected efficacy end points, and rigorous methodological approach aim to evaluate personalized therapeutic interventions with unprecedented precision.

BESPOKE: Study Design, Efficacy End Points, and Methods

Panelists discuss how the BESPOKE trial enrolled a diverse cohort of patients with varying demographic profiles, disease stages, comorbidities, and treatment histories to ensure comprehensive representation for personalized medicine approaches.

Overview of BESPOKE Patient Characteristics

Panelists discuss how BESPOKE trial results demonstrate significantly improved disease-free survival rates in patients with negative circulating tumor DNA (ctDNA) status compared with those with detectable ctDNA, underscoring its potential as a powerful prognostic biomarker.

BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status 

Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.

Panelists discuss how minimal residual disease (MRD) status, as detected through circulating tumor DNA (ctDNA) analysis, can guide personalized treatment decisions by identifying patients who may benefit from intensification of adjuvant therapy and those who could safely undergo de-escalation of treatment regimens.

Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy 

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

BESPOKE: ctDNA Clearance During and After ACT

EP: 1.The Role of ctDNA in CRC

EP: 2.BESPOKE: Study Design, Efficacy End Points, and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

EP: 5.BESPOKE: ctDNA Clearance During and After ACT

EP: 6.Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

Newsletter